Bridgeway Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Bridgeway Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-52,783	Closed	-$272K	–	1422
2019 Q2	$272K	Sell	52,783 -150,500	-74%	-$676K	﹤0.01%	1119
2019 Q1	$732K	Hold	203,283	–	–	0.01%	874
2018 Q4	$1.25M	Buy	203,283 +40,500	+25%	+$247K	0.02%	652
2018 Q3	$951K	Hold	162,783	–	–	0.01%	897
2018 Q2	$692K	Hold	162,783	–	–	0.01%	1025
2018 Q1	$718K	Sell	162,783 -11,800	-7%	-$52.6K	0.01%	960
2017 Q4	$918K	Buy	174,583 +39,800	+30%	+$243K	0.01%	869
2017 Q3	$826K	Hold	134,783	–	–	0.01%	911
2017 Q2	$974K	Hold	134,783	–	–	0.01%	837
2017 Q1	$714K	Buy	134,783 +47,800	+55%	+$323K	0.01%	936
2016 Q4	$625K	Hold	86,983	–	–	0.01%	991
2016 Q3	$814K	Hold	86,983	–	–	0.01%	886
2016 Q2	$550K	Buy	86,983 +40,000	+85%	+$257K	0.01%	1007
2016 Q1	$259K	Buy	+46,983	New	+$177K	﹤0.01%	1247

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Bridgeway Capital Management's PETX Position: Q3 2019 in Review

Bridgeway Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 52,783 shares — an estimated $272K sold.

Bridgeway Capital Management first reported a position in PETX in Q1 2016 and held it in 14 quarters. The position peaked at $1.25M in Q4 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Bridgeway Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Bridgeway Capital Management sold 52,783 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $272K.
Bridgeway Capital Management first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 14 quarters.
Bridgeway Capital Management's Aratana Therapeutics, Inc. position peaked at $1.25M in Q4 2018.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Bridgeway Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.